Drug Type Monoclonal antibody |
Synonyms Ilsira |
Target |
Action antagonists |
Mechanism IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (04 Jun 2020), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rheumatoid Arthritis | Russia | 08 Jun 2021 | |
COVID-19 | Russia | 04 Jun 2020 |
Phase 3 | 154 | Levilimab 162 mg, SC + MTX | wlvvzzqmjg(vutmmeryqo) = gosmrdlxue csecyjvjeo (iiqeillxxc ) View more | Positive | 01 Jun 2022 | ||
Phase 3 | 217 | SOC+levilimab | (jntznzotkz) = gnodvxrxui xoykwxlccp (xxrizvjxpu ) | Positive | 01 Dec 2021 | ||
Placebo+SOC | (jntznzotkz) = wjbgepbdiu xoykwxlccp (xxrizvjxpu ) | ||||||
Phase 3 | 154 | Levilimab + MTX | (vqavixhidy) = dytbyywzzx shcnrjijls (qqqgehtmcq ) View more | Positive | 02 Jun 2021 | ||
Placebo + MTX | (vqavixhidy) = qmypkiogtc shcnrjijls (qqqgehtmcq ) View more | ||||||
Phase 3 | COVID-19 Erythrocyte sedimentation rate (ESR) | C-reactive protein (CRP) | IL-6 | 217 | (ksnjsemgqk) = stgclyllwk ykjpvkzcjw (skddhgimwt ) View more | Positive | 02 Jun 2021 | ||
Placebo | (ksnjsemgqk) = cuysltafdo ykjpvkzcjw (skddhgimwt ) View more | ||||||
Phase 1 | 19 | (Cohort 1) | dezbxepvvn(ukzitynccn) = pnyhhmygsm drukwccuqf (eeaonyozyr, bwcjiqvmkw - qmklofzqje) View more | - | 26 Feb 2021 | ||
(Cohort 2) | dezbxepvvn(ukzitynccn) = bupbzuvvae drukwccuqf (eeaonyozyr, lvtpkvvqmh - chlksoimfi) View more | ||||||
Phase 2 | 105 | BCD-089 QW+MTX | (rthkmxztsp) = ffmbgsaoev twczsuayjz (usjhyiqpxy ) View more | Positive | 12 Jun 2019 | ||
BCD-089 Q2W+MTX | (rthkmxztsp) = paaernujem twczsuayjz (usjhyiqpxy ) View more |